Evidence map›Paper›PMID 41121279›Full record

ArticleAntimicrobial resistance and infection control2025

The impact of carbapenem-resistant infections in intensive care units: focus on non-fermenting gram-negative bacilli and survival analysis.

Juliette Dessemon, Charles-Hervé Vacheron, Anne Savey, Anaïs Machut, Arnaud Friggeri, Claire Prevot, Xavier Bourge, Alain Lepape, Christelle Elias, REA-REZO Study Group

Abstract read
In one paragraph

Article in Antimicrobial resistance and infection control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Six Years ofAntibiotics (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Juliette DessemonService Hygiène, Epidémiologie, Infectiovigilance et Prévention, Hospices Civils de Lyon, Lyon, France. juliette.dessemon@chu-lyon.fr.
Charles-Hervé VacheronPublic Health, Epidemiology & Evolutionary Ecology of Infectious Diseases (PHE3ID) Team, Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, CNRS UMR5308, ENS de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Anne SaveyREA-REZO Infections Et Antibiorésistance en Réanimation, Lyon, France.
Anaïs MachutREA-REZO Infections Et Antibiorésistance en Réanimation, Lyon, France.
Arnaud FriggeriPublic Health, Epidemiology & Evolutionary Ecology of Infectious Diseases (PHE3ID) Team, Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, CNRS UMR5308, ENS de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Claire PrevotMSD France, Puteaux, France.
Xavier BourgeMSD France, Puteaux, France.
Alain LepapePublic Health, Epidemiology & Evolutionary Ecology of Infectious Diseases (PHE3ID) Team, Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, CNRS UMR5308, ENS de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Christelle EliasService Hygiène, Epidémiologie, Infectiovigilance et Prévention, Hospices Civils de Lyon, Lyon, France.
REA-REZO Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCarbapenem-resistant non-fermenting Gram-negative bacilli (CR Nf-GNB) infections present a significant challenge in intensive care units (ICUs). Despite being recognized as a significant clinical problem, comprehensive studies on the impact of CR Nf-GNB infections on patient morbidity and mortality remained limited.

methodsUsing data from the REA-REZO surveillance network, which includes 206 adult ICUs in France, we analysed patients admitted between 2016 and 2022 who developed healthcare-associated infections caused either by CR Nf-GNB or carbapenem-susceptible (CS) Nf-GNB. Propensity scores were calculated using a logistic regression model including relevant covariates, and CR and CS Nf-GNB patients were matched 1:1. The primary outcome was 30-day ICU survival, and secondary outcomes included 30-day reinfection (different pathogen) and relapse (same pathogen) rates.

resultsAmong the 17,527 Nf-GNB infections, 3,171 were caused by CR strains. After matching, 1,498 patients were included in each group. CR Nf-GNB infections were independently associated with a significantly higher risk of death (adjusted sub-Hazard Ratio [sHR] 1.57 [95% CI, 1.40-1.76]) and increased reinfection rates (sHR 1.23 [95% CI, 1.01-1.50]) compared to CS Nf-GNB infections. CR infections also showed a higher proportion of reinfections with multidrug-resistant organisms.

conclusionCR Nf-GNB infections in ICU patients significantly increased mortality, and the risk of reinfection. CR Nf-GNB was not associated with a higher risk of relapse. These findings underscore the importance of targeted infection control measures and novel treatment strategies to manage CR Nf-GNB in critical care settings.

Indexed as

Anti-Bacterial AgentsCarbapenemsCross InfectionGram-Negative BacteriaGram-Negative Bacterial InfectionsIntensive Care UnitsAdultAgedFemaleFranceHumansMaleMiddle AgedSurvival AnalysisAnti-Bacterial AgentsCarbapenemsCarbapenemsGram-negative bacteriaHealthcare-associated infectionIntensive care unitMortalityPseudomonas aeruginosaSurveillance

Identifiers

PMID41121279
PMCPMC12542083

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.